Aldeyra Therapeutics
NASDAQ: ALDXLexington, US · Delaware corporation · 1 known investors
Find your way into Aldeyra Therapeutics
167 people in our graph share verified history with the Aldeyra Therapeutics team — schools, employers, funds. One of them is your warm intro.
Daniel Demmerunlockedknows Stephen Tulipano · together at Digital Equipment (DEC) (overlapped)
×4knows the team · via Digital Equipment (DEC)
knows the team · via United States Navy
×2knows the team · via United States Army
knows the team · via Salem State University
×3knows the team · via Suffolk University - Sawyer Business School
Aldeyra Therapeutics is a biopharmaceutical company developing therapies for eye diseases and other conditions. The company is led by a board of experienced pharmaceutical and life sciences executives.
Founders & leadership
TC
Todd C. BradyinChief Executive Officer
ST
Stephen TulipanoinCFO2014–2018Stephen Tulipano is Chief Financial Officer at Aldeyra Therapeutics, a biopharmaceutical company developing therapies for eye diseases. He has held increasingly senior finance and operations leadership roles in the pharmaceutical, biopharmaceutical, and technology sectors, with expertise in capital raising, mergers and acquisitions, accounting, and corporate strategic planning.
SL
Scott L. YounginExecutiveScott L. Young has held executive roles for 17 years within biotechnology and pharmaceutical companies, with experience across the full development lifecycle from early-stage research through clinical trials and public offerings.
DB
Dr. BradyPresident and Chief Executive Officer
Board
JI
BB
Ben BronsteinBoard director
GP
Gary PhillipsBoard director
NW
Neal WalkerBoard director
MJ
Martin J. JoyceBoard director
CB
C. Boyd ClarkeBoard director
DB
Dr. BronsteinBoard Member
Investors · 1
Reported raises · per SEC filings
Form D private placements$19.8M disclosed across 3 rounds · 2015–2019
▶$10MraisedFeb 2019 · 37 investors · BiotechnologyRule 506(b)
▶$10MraisedFeb 2019 · 37 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard DouglasDirector
- Neal WalkerDirector
- Martin J. JoyceDirector
- Jesse I. TreuDirector
- Todd BradyExecutive Officer, Director
- David L. ClarkExecutive Officer
- Ben BronsteinDirector
- David McMullinExecutive Officer
- Gary PhillipsDirector
- Stephen MachathaExecutive Officer
- Joshua ReedExecutive Officer
- Offering amount
- $25M
- Amount sold
- $10M
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedFeb 2015 · 1 investors · BiotechnologyRule 506(b)
▶$2MraisedFeb 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jesse I. TreuDirector
- Neal WalkerDirector
- Stephen TulipanoExecutive Officer
- Scott YoungExecutive Officer
- C.Boyd ClarkeDirector
- Ben BronsteinDirector
- Martin J. JoyceDirector
- Gary PhillipsDirector
- Todd C. BradyExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $2M
- First sale
- Jan 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.8MraisedJan 2015 · 16 investors · BiotechnologyRule 506(b)
▶$7.8MraisedJan 2015 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Todd C. BradyExecutive Officer, Director
- Ben BronsteinDirector
- Stephen TulipanoExecutive Officer
- Gary PhillipsDirector
- Neal WalkerDirector
- Jesse I. TreuDirector
- Scott L. YoungExecutive Officer
- Martin J. JoyceDirector
- C. Boyd ClarkeDirector
- Offering amount
- $18.4M
- Amount sold
- $7.8M
- First sale
- Jan 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$71.9Mvaluation at IPOMay 2015 · $7.50/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Aldeyra Therapeutics, Inc. Quarterly Earnings Report | ALDX Form 10-Qstocktitan.net · Aug 2026Frequently asked questions
- What does Aldeyra Therapeutics do?
- Aldeyra Therapeutics is a biopharmaceutical company developing therapies for eye diseases and other conditions. The company is led by a board of experienced pharmaceutical and life sciences executives.
- Who are Aldeyra Therapeutics's investors?
- Aldeyra Therapeutics's investors include Domain Associates.
- How much funding has Aldeyra Therapeutics raised?
- Aldeyra Therapeutics has disclosed $19.8M raised across 3 rounds.
- Where is Aldeyra Therapeutics headquartered?
- Aldeyra Therapeutics is headquartered in Lexington, US.